Tempus, a leader in artificial intelligence and precision medicine, today announced its new, state-of-the-art genomic sequencing lab in Durham’s Research Triangle Park (RTP). The 52,000-square foot space marks Tempus’ third laboratory, joining the company’s existing CAP-accredited/CLIA-certified labs in Atlanta and its Chicago headquarters. RTP’s proxi...
Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology...
Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity an...
Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of six new hires to the leadership team, including a new Chief Commercial Officer, Chief Financial Officer, General Counsel, and the company’s first Chief Accounting Officer, Senior Vice President of Marketing, and Senior Vice President of Cor...
Tempus-authored, Annals of Oncology — Background The KRAS G12C inhibitor sotorasib has shown promising anticancer activity in patients with advanced solid tumors harboring the KRAS G12C mutation, holding the potential for transforming clinical management of KRAS mutated solid tumors. The distribution of KRAS variants, including G12C in...
Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 - 8. “These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35 pe...
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens. The all-in-one platform will provide scientists and researchers across biotechnology and pharmaceutical companies with short term, on demand access to more than 35 petabytes of de-identified cli...
Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. The RWE Alliance intends t...
From the beginning of the pandemic, health experts were concerned that millions of Americans would defer treatment of existing illnesses—including cancer—and postpone routine preventative screenings given the justifiable fear of contracting COVID-19. Now, more than a year after COVID-19 forced the country to a complete halt, a clearer picture is starting to eme...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will convene virtually on April 10-15 and May 17-21. The research leverages Tempus’ unparalleled library of multi-modal data to facilitate discovery, development, and delivery of opt...
